64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Production

64x Bio, enabling next-generation medicines, Lexi Rovner, PhD, George Church, PhD, David Thompson, PhD, Pamela Silver, PhD, Jeffrey Way, PhD, and the team, has announced the launch of LV Apex Suite, a new product line designed to support high-performance lentiviral vector manufacturing.

Platform Expansion.

The product launch marks 64x Bio's expansion into lentiviral vector production, extending the capabilities of its VectorSelect platform beyond adeno-associated virus (AAV) manufacturing. Following the launch of the AAV Apex Suite in 2025, the company is applying its data-driven platform across additional therapeutic modalities, beginning with lentiviral vectors and expanding into CHO-based biologics manufacturing, with further product announcements planned.

Addressing Lentiviral Vector Manufacturing.

Lentiviral vectors play a critical role in the production of cell and gene therapies, including CAR-T treatments and emerging in vivo CAR-T approaches. However, manufacturers continue to face challenges related to productivity, consistency, scalability, and process complexity.

64x Bio's LV Apex Suite is designed to address these limitations by providing high-performance lentiviral vector production technologies. Its first product, a suspension-adapted transient cell line, delivers functional titers of 4E8 TU/mL, and has already attracted multiple commercial collaborations.

Leadership Perspective.

Lexi Rovner, PhD, CEO and Co-founder of 64x Bio, described the launch of LV Apex Suite as an important milestone that expands the company's product portfolio and marks the beginning of a broader roadmap spanning additional cell lines and reagents.

Scientific Advisory Board Member Mathew Pletcher, PhD, highlighted the successful application of 64x Bio's production system optimization platform across multiple modalities, including adeno-associated virus (AAV), lentiviral vectors, and the company's expanding biologics manufacturing capabilities.

CellMap Platform.

At the core of 64x Bio's platform is CellMap, a growing dataset that connects genetic and metabolic characteristics with manufacturing productivity. These insights enable the company to develop engineered cell lines and reagents across multiple therapeutic modalities.

As the platform expands from adeno-associated virus (AAV) to lentiviral vectors (LV) and additional product suites, CellMap continues to accumulate data that supports more systematic product development. The company is also leveraging the dataset to train internal AI models aimed at improving future cell line engineering and reagent optimization.